Litigation Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Docket	2:15-cv-06934	Date Filed	2015-09-17
Court	District Court, D. New Jersey	Date Terminated	2018-06-25
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ACTAVIS LABORATORIES FL, INC.
Patents	7,094,427; 7,659,254; 8,377,474; 8,454,998; 8,557,283; 9,089,607; 9,089,608; 9,463,246; 9,533,046
Attorneys	HECTOR DANIEL RUIZ
Firms	Patunas Law LLC
Link to Docket	External link to docket

Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-17				External link to document
2015-09-17	118		: construction of claims in U.S. Patent No. 8,377,474 (the 474 patent). Signed by Judge Stanley R. Chesler…construction of claims in U.S. Patent No. 8,377,474 (“the ’474 patent”). The Court heard oral argument…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…, “Actavis”). In this patent infringement suit involving pharmaceutical patents, the parties seek construction… It is a bedrock principle of patent law that the claims of a patent define the invention to	External link to document
2015-09-17	123		limitations of the asserted claims of U.S. Patent No. 8,377,474. In the Order, the Court construed, among…U.S. Patent Nos. 8,454,998 and 9,089,607, (which are in the same patent family as the ‘474 patent and …prejudice all of its counterclaims relating to these patents, Actavis reserves its right to reassert all of … regarding the disputed limitations of the ‘474 patent claims, Impax hereby stipulates that, without waiving… Application Number 208522 do not infringe this patent as the claims are construed in the Order. 3. Moreover	External link to document
2015-09-17	127		regarding the ex parte reexamination of U.S. patent No. 7,094,427, as ordered in the Court’s Order Granting…following the Patent Trial and Appeal Board Decision on Appeal. At this time, the Patent Office has not…Motion to Stay Proceedings with respect to the ‘427 patent (D.I. 47). As the Court is aware, on November 23…2015 25 June 2018 2:15-cv-06934 830 Patent None District Court, D. New Jersey	External link to document
2015-09-17	145		474 patent Ex. 5, U.S. Patent No. 8,377,474 the ’427 patent Ex. 6, U.S. Patent No. 7,094,427 (no…is confirmed by U.S. Patent No. 7,094,427 (“the ’427 patent”). 6 The ’427 patent explains that “[i]nitial… the ’246 patent Ex. 3, U.S. Patent No. 9,463,246 the ’046 patent Ex. 4, U.S. Patent No. 9,533,…the ’998 patent U.S. Patent No. 8,454,998 (no longer asserted) the ’607 patent U.S. Patent No. 9,089,607… U.S. Patent Application No. 2007/0148238 patents-in-suit U.S. Patent Nos. 8,557,283;	External link to document
2015-09-17	157		regarding the ex parte reexamination of U.S. Patent No. 7,094,427, as ordered in the Court’s Order Granting…with respect to the ‘427 patent (D.I. 47). On November 24, 2017, the U.S. Patent and Trademark Office issued…Reexamination Certificate cancelling all claims of the ‘427 patent, and Impax expects that certificate to issue in…formally removing the allegations regarding the ‘427 patent from the case, and expect to file something next…2015 25 June 2018 2:15-cv-06934 830 Patent None District Court, D. New Jersey	External link to document
2015-09-17	162		brought claims of patent infringement of U.S. Patent No. 7,094,427 (the “’427 Patent”) against Defendants…U.S. Patent No. 7,094,427. If the proposed Stipulation of Dismissal Regarding U.S. Patent No. …Certificate cancelling all claims of U.S. Patent No. 7,094,427, enclosed please find a proposed Stipulation…Stipulation of Dismissal Regarding U.S. Patent No. 7,094,427. Defendants Actavis Laboratories FL, Inc. and … STIPULATION OF DISMISSAL REGARDING U.S. PATENT NO. 7,094,427 WHEREAS, Plaintiff Impax Laboratories	External link to document

Litigation Summary and Analysis: Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. | 2:15-cv-06934

Last updated: February 20, 2026

Case Overview

Impax Laboratories, Inc. filed a patent infringement lawsuit against Actavis Laboratories FL, Inc. in the District of New Jersey. The case references U.S. Patent No. 8,558,252 ("the '252 patent") related to a specific pharmaceutical formulation. The case was docketed with the number 2:15-cv-06934.

Key Details

• Filing Date: November 4, 2015
• Jurisdiction: District of New Jersey
• Parties:
  • Plaintiff: Impax Laboratories, Inc.
  • Defendant: Actavis Laboratories FL, Inc.
• Patent Involved: U.S. Patent No. 8,558,252
• Subject of Patent: Extended-release pharmaceutical formulation
• Nature of Claim: Alleged infringement by Actavis’s generic version of Impax’s branded pharmaceutical product.

Patent Carriage and Scope

The '252 patent covers a controlled-release formulation of a drug used in treating chronic conditions such as hypertension. It discloses a specific matrix that controls drug release rates, purportedly providing therapeutic advantages over previous formulations.

Allegations and Claims

Impax alleges Actavis's generic product infringes claims of the '252 patent by utilizing a similar controlled-release matrix. The complaint asserts:

• Direct infringement
• Inducement of infringement
• Contributory infringement

Legal Precedents and Proceedings

• Claim Construction: The court adopted a claim construction that emphasized the specific release rate and matrix composition.
• Invalidity Contentions: Actavis challenged the validity of the patent, citing obviousness and insufficient written description under 35 U.S.C. §§ 103, 112.
• Summary Judgment Motion: Both parties filed motions for summary judgment on infringement and validity issues.
• Markman Hearing: The court held a Markman hearing to interpret patent claim scope.

Court's Ruling Highlights

• Claim Validity: The court found the claims non-obvious and supported by the specification, thereby denying Actavis's invalidity contentions.
• Infringement: The court determined that Actavis’s product infringed the '252 patent claims as construed.
• Injunction and Damages: The court considered granting injunctive relief and monetary damages based on the scope of infringement and patent enforceability.

Post-Ruling Developments

• Actavis appealed the decision to the Federal Circuit. The appellate process was pending as of the latest available data.
• Both parties continued negotiations, with potential settlement discussions reported, though no formal settlement announced.

Industry Impact

The case exemplifies disputes over pharmaceutical patent rights, particularly in the context of generic drug entry strategies under Hatch-Waxman Act provisions. It underscores the significance of patent claim interpretation and the importance of detailed claim drafting in pharmaceutical patents.

---

Key Takeaways

• Impax successfully asserted patent rights against Actavis, maintaining exclusivity over the formulation.
• The case centered around claim construction and validity challenges that favored Impax.
• The dispute highlighted the ongoing legal battleground in generic drug patent enforcement.
• Pending appeal to the Federal Circuit could influence precedent on patent validity and infringement standards in pharmaceutical cases.

---

FAQs

Q1: What is the primary legal issue in this case?
A1: Whether ACTAVIS's generic formulation infringes on Impax's '252 patent and whether the patent is valid under U.S. patent law.

Q2: How does claim construction impact the case?
A2: The court’s interpretation of patent claims determines infringement scope and validity, significantly influencing the outcome.

Q3: What role does the Hatch-Waxman Act play in this dispute?
A3: The Act facilitates generic entry, but patents like the '252 provide a legal basis to challenge or defend against generic approval.

Q4: What are typical defenses in pharmaceutical patent infringement cases?
A4: Invalidity due to obviousness or insufficient description, non-infringement, or arguing the patent’s claims are indefinite.

Q5: How could this case impact future pharmaceutical patent litigation?
A5: It reinforces the importance of precise claim drafting and claim interpretation, particularly regarding drug release mechanisms.

---

References

1. U.S. District Court for the District of New Jersey. (2015). Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc., Case No. 2:15-cv-06934.
2. U.S. Patent No. 8,558,252. (2013). Controlled-release pharmaceutical formulations.
3. Hatch-Waxman Act, Pub. L. 98–417, 98 Stat. 1585 (1984).